Tunisia just became one of the first governments to help cover the cost of a gluten-free diet, global regulators adopted the first science-based threshold for “may contain” gluten warnings, and the UK updated how doctors diagnose celiac disease in adults. This edition of The Gluten-Free Brief also covers a patient registry finding that most people with celiac disease don’t feel fully informed at diagnosis, new research on celiac screening in children with type 1 diabetes, and recent gluten and wheat recalls across the US, Canada, the UK, Australia, and Europe.
Tunisia just quadrupled its gluten-free food allowance.
A new decree raises the monthly allowance for low-income people with celiac disease or wheat/gluten hypersensitivity from 30 to 130 dinars — about $44 a month — and puts the increase into effect. To qualify, families must be registered in Tunisia’s Social Safety Net Program and have the diagnosis certified by a medical committee.
Sources: Official Gazette of Tunisia, Issue 70, July 14, 2026; Finance Law No. 48 of 2024, Article 26; 2026 Finance Law, Article 35
The UK just changed how some adults get diagnosed with celiac disease.
Under new BSG guidance, adults with antibody levels above 10x the normal limit — confirmed by a second blood test — can skip the biopsy entirely, covering an estimated 20–30% of symptomatic adults. Everyone else still needs one, since a single result alone isn’t conclusive enough. Either way, a specialist must confirm it, not a GP. Patients should also continue eating gluten until testing is complete.
Sources: Coeliac UK (BSG guideline explainer); British Society of Gastroenterology, July 20, 2026
Only 3 in 10 people felt informed at diagnosis.
CDF’s iCureCeliac registry surveyed 18,000+ people with celiac disease and found just 29.8% strongly agreed their doctor clearly explained how to manage the disease when they were diagnosed, suggesting many patients leave that first appointment without a clear plan for a lifelong condition.
Sources: Celiac Disease Foundation, iCureCeliac Patient Registry, July 18, 2026
Children with type 1 diabetes should be screened for celiac disease — and a Saudi study just reinforced why.
Among 407 kids with T1D, about 13.7% of those screened for celiac tested positive, alongside elevated thyroid dysfunction and vitamin D deficiency. It’s not a one-off: multiple Saudi studies over the past decade have found similarly high rates, consistently among the highest reported in published studies. Not a breakthrough, but a solid reminder to keep celiac screening routine in T1D care.
Sources: Almansour S, et al. Cureus, May 20, 2026; celiac.com, July 18, 2026.
Gluten just got its first science-based threshold for “may contain” warnings.
The Codex Alimentarius Commission adopted a 4 mg gluten reference dose for precautionary allergen labeling this month — a global first. It doesn’t touch the 20 ppm “gluten-free” threshold; it only standardizes when a cross-contact warning is warranted. AOECS, CDF, Celiac Canada, and Coeliac UK all pushed for it. The guidance is advisory, so implementation will depend on how individual countries incorporate it into national regulations.
Sources: Codex Alimentarius Commission, adopted July 2026; CDF; AOECS
Allergen recalls: gluten/wheat watch.
Six recent undeclared-wheat or -gluten alerts: Capsicana’s Easy Going Mild Salsa (UK), Highgate Tender Meats’ Honey Garlic Sausage (Canada), Street’s Teriyaki Beef Jerky public health alert (US), Truong Ton Group’s Vietnamese Sausage (Australia), Milka Choco Jaffa Orange biscuits (Central/Eastern Europe), and Delhaize gluten-free oatmeal (Netherlands, withdrawn over possible cross-contact with gluten). If any of these are in your pantry, check the recall notice.
Sources: UK FSA, CFIA, USDA-FSIS, FSANZ, Il Fatto Alimentare, Nederlandse Coeliakie Vereniging (July 2026)
The Gluten-Free Brief is a twice-monthly informational news roundup from the Gluten-Free Food Program. It is provided for educational purposes and does not replace medical advice from qualified professionals. Inclusion of any product, brand, or organization does not imply endorsement by GFFP. Previous editions can be found here and on our LinkedIn, Instagram, and TikTok.
